Gender assignment and hormonal treatment for disorders of sexual differentiation.
OBJECTIVE
To study the gender assignment and hormonal treatment advocated for disorders of sexual differentiation (DSD).


METHODS
A study was done on patients who were reviewed in the Pediatric Intersex Clinic to evaluate the pattern of gender assignment and hormonal treatment advocated.


CONCLUSIONS
The patients included male pseudohermaphrodite (MPH) 169; congenital adrenal hyperplasia (CAH) 91; mixed gonadal dysgenesis (MGD) 29; true hermaphrodite (TH) 25; pure gonadal dysgenesis (PGD) 2; persistent mullerian duct syndrome (PMDS) 2 and others (micropenis, severe hypospadias with cryptorchidism, 46XX male) 39. Out of 91 cases of CAH, 70 (76.9%) were on steroids (prednisolone, hydrocortisone) and/or mineralocorticoids (fluoricortisone) for adrenal suppression. Out of 146 cases of male pseudohermaphrodite and 21 cases of true hermaphrodite and 3 cases of mixed gonadal dysgenesis reared as males, testosterone was given for local application for phallic growth in 101 and/or as systemic injection for mental makeup after puberty in 41 cases. Systemic testosterone injection was also given for 7 cases of CAH reared as males. Out of 26, 15 cases with mixed gonadal dysgenesis and one out of 2 cases of pure gonadal dysgenesis that attained puberty after being reared as females, after female genitoplasty, were given conjugated oestrogen (Premarin) supplemented with progesterone, as the uterus was preserved. For 12 post-pubertal cases of complete androgen insensitivity syndrome (AIS), only premarin was given as there was no uterus. Growth hormone and Gn RH analogue was given in 2 patients with CAH to tide over the early bone maturation induced by hormones with equivocal results. Thus judicious hormonal supplementation based upon type of DSD and gender assigned can provide a psychological and cosmetic benefit to patients with DSD.
Sharma
Shilpa
S
Department of Pediatric Surgery, All India Institute of Medical Sciences, New Delhi, India.
Gupta
D K
DK
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000465:Algorithms; D000728:Androgens / Q000627:therapeutic use; D012734:Disorders of Sex Development / Q000628:therapy*; D004967:Estrogens / Q000627:therapeutic use; D004966:Estrogens, Conjugated (USP) / Q000627:therapeutic use; D005260:Female; D005783:Gender Identity; D005835:Genitalia / Q000601:surgery; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives; D019382:Human Growth Hormone / Q000627:therapeutic use; D006801:Humans; D008297:Male; D011374:Progesterone / Q000627:therapeutic use; D011372:Progestins / Q000627:therapeutic use; D013739:Testosterone / Q000627:therapeutic use; D013520:Urologic Surgical Procedures
D000305:Adrenal Cortex Hormones; D000728:Androgens; D004967:Estrogens; D004966:Estrogens, Conjugated (USP); D011372:Progestins; D019382:Human Growth Hormone; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone; D011374:Progesterone